

World Journal of *Clinical Cases*

World J Clin Cases 2023 November 16; 11(32): 7741-7939



Contents

Thrice Monthly Volume 11 Number 32 November 16, 2023

EDITORIAL

- 7741 Efficacy of probiotics supplementation in amelioration of celiac disease symptoms and enhancement of immune system

Moawad MHE, Alkhawaldeh IM, Naswhan AJ

ORIGINAL ARTICLE

Retrospective Cohort Study

- 7745 Effect of enhanced recovery after surgery with multidisciplinary collaboration on nursing outcomes after total knee arthroplasty

Liu J, Zheng QQ, Wu YT

Retrospective Study

- 7753 Appropriate leucine-rich α -2 glycoprotein cut-off value for Japanese patients with ulcerative colitis

Yamazato M, Yanai S, Oizumi T, Eizuka M, Yamada S, Toya Y, Uesugi N, Sugai T, Matsumoto T

- 7761 Association between depressive mood and body image and menopausal symptoms and sexual function in perimenopausal women

Ling J, Wang YH

- 7770 Clinical study of NFNC in the treatment of acute exacerbation chronic obstructive pulmonary disease patients with respiratory failure

Chen X, Dai L, Ma JZ, Chu XX, Dai L, Liu JM, Guo SW, Ru XW, Zhuang XS

- 7778 Mortal condition in an unusual localization, analysis of isolated tongue and tongue base abscesses

Bal KK, Gür H, Demir I, Ismi O, Vayisoglu Y, Gorur K, Ozcan C, Unal M

- 7785 Adult-onset hypophosphatemic osteomalacia as a cause of widespread musculoskeletal pain: A retrospective case series of single center experience

Kim S, Kim SW, Lee BC, Kim DH, Sung DH

Prospective Study

- 7795 Efficacy and safety of laparoscopic vs open gastrectomy after neoadjuvant therapy for locally advanced gastric cancer

Yu CD, Zhang K

Randomized Controlled Trial

- 7806 Effect of anesthesia induction with butorphanol on postoperative nausea and vomiting: A randomized controlled trial

Xie F, Sun DF, Yang L, Sun ZL

Randomized Clinical Trial

- 7814** Efficacy and safety of aspirin antiplatelet therapy within 48 h of symptom onset in patients with acute stroke
Zhang JQ, Pan ZB

META-ANALYSIS

- 7822** Analysis of the effectiveness of cognitive rehabilitation for patients with chronic mental illness: A meta-analysis
Jang JS, Oh S, Kim G, Lee N, Song H, Park J, Lee Y, Kim M, Kwon M

SCIENTOMETRICS

- 7833** Emerging trends and hotspots of Nuclear factor erythroid 2-related factor 2 in nervous system diseases
Chang XQ, Xu L, Zuo YX, Liu YG, Li J, Chi HT

CASE REPORT

- 7852** Transcatheter embolization for hemorrhage from aberrant testicular artery after partial nephrectomy: A case report
Youn J, Choi MJ, Kim BM, Seo Y
- 7858** Persistent left superior vena cava in right hemiarch replacement under deep hypothermic circulatory arrest: A case report
Mi ZY, He G, Gao HL, Li C
- 7865** Type II Abernethy malformation with cystic fibrosis in a 12-year-old girl: A case report
Zhang LJ, Liu XY, Chen TF, Xu ZY, Yin HJ
- 7872** Glucocorticoid reduction induced chorea in pediatric-onset systemic lupus erythematosus: A case report
Xu YQ, Wang M, Zhang Y
- 7876** Primary pulmonary lymphoepithelioma-like carcinoma misdiagnosed as lung squamous cell carcinoma: A case report
Yin CJ, Wang GJ, Su XM, Li D
- 7881** Median arcuate ligament syndrome complicated with gallbladder stones: A case report
Dang JQ, Wang QQ, Yang YL, Shang L, Bian QT, Xiang HJ
- 7888** Uterine rupture due to adenomyosis in an adolescent: A case report and review of literature
Kim NI, Lee JS, Nam JH
- 7895** Multiple therapies relieve long-term tardive dyskinesia in a patient with chronic schizophrenia: A case report
Ly L, Guo P, Feng M, Fang Y, Wang SK, Chen HX
- 7900** Lung ultrasound for the early diagnosis of acute lung injury: A case report
Zheng X, Liu N

- 7905** New treatment for gastric duplication cyst: Endoscopic ultrasonography-guided fine-needle aspiration combined with lauromacrogol sclerotherapy: A case report
Bu YW, Han RQ, Ma WQ, Wang GN, Er LM
- 7911** Immunotherapy in SMARCB1 (INI-1)-deficient sinonasal carcinoma: Two case reports
Zhang L, Gao AX, He YL, Xu MJ, Lu HJ
- 7920** Interstitial pneumonia combined with nocardia cyriacigeorgica infection: A case report
Qi DD, Zhuang Y, Chen Y, Guo JJ, Zhang Z, Gu Y
- 7926** Intracranial infection accompanied sweet's syndrome in a patient with anti-interferon- γ autoantibodies: A case report
Zheng JH, Wu D, Guo XY

LETTER TO THE EDITOR

- 7935** Potential and limitations of ChatGPT and generative artificial intelligence in medical safety education
Wang X, Liu XQ

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Guo-Xin Ni, MD, PhD, Chief Doctor, Professor, School of Sport Medicine and Rehabilitation, Beijing Sport University, Beijing 100084, China. guoxinni@bjmu.edu.cn

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCC as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin, Production Department Director: Xu Guo, Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Salim Surani, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

November 16, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Retrospective Study

Association between depressive mood and body image and menopausal symptoms and sexual function in perimenopausal women

Jia Ling, Yu-Hong Wang

Specialty type: Psychology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Griffiths M, United Kingdom; Mastrantonio E, Italy

Received: August 16, 2023

Peer-review started: August 16, 2023

First decision: August 31, 2023

Revised: September 19, 2023

Accepted: November 8, 2023

Article in press: November 8, 2023

Published online: November 16, 2023



Jia Ling, Yu-Hong Wang, Institute of Innovation and Applied Research in Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, Hunan Province, China.

Corresponding author: Yu-Hong Wang, PhD, Doctor, Institute of Innovation and Applied Research in Chinese Medicine, Hunan University of Chinese Medicine, No. 300 Xueshi Road, Hanpu Science and Education Park, Changsha 410208, Hunan Province, China.
ojhtgb000@163.com

Abstract

BACKGROUND

Perimenopausal is the period when women's ovarian function begins to decline before and after menopause. During this period, women experience a series of mental state changes, such as decreased hormone levels, decreased libido, and even female sexual dysfunction (FSD) in severe cases, which reduces their quality of life. Factors affecting the occurrence of FSD include physiological and non-physiological factors, among which physiological factors are uncontrollable. Therefore, it is particularly important to ascertain the related non-physiological factors that affect the occurrence of FSD for improving the quality of sexual life of perimenopausal women.

AIM

To investigate the mediating effect of depressive mood and body image on menopausal symptoms and sexual function in perimenopausal women.

METHODS

A total of 186 perimenopausal women were enrolled between January 2019 and January 2021 and divided into the FSD (134 cases) and control (52 cases) groups based on the presence and absence of FSD. Clinical data were compared between the two groups. FSD-related factors were analyzed using logistic regression analysis. Hamilton Depression Scale (HAMD), Body Image Scale (BIS), and Menopause Rating Scale (MRS) scores were compared among women with different FSD scores. The correlation of the MRS score with the BIS and HAMD scores and the mediating effect of the BIS and HAMD scores on the MRS score and female sexual function index (FSFI) were analyzed.

RESULTS

The HAMD and BIS scores were higher in the FSD group than in the control group, and the difference in monthly income between the two groups was statistically significant (all $P < 0.05$). Monthly income of < 2000 yuan [odds ratio (OR) = 26.586, $P = 0.000$], BIS score (OR = 1.590, $P = 0.000$), and HAMD score (OR = 1.884, $P = 0.000$) were independent risk factors for FSD. MRS scores were positively correlated with BIS and HAMD scores ($r = 0.358$ and 0.244 , $P = 0.000$ and 0.001 , respectively) and negatively correlated with FSFI scores ($r = -0.433$, $P = 0.000$). Body image and depressive mood had partial mediating effects, accounting for 39.90% of the total effect.

CONCLUSION

Depression and body image play mediating roles between menopausal symptoms and sexual function in perimenopausal women.

Key Words: Perimenopause; Depressive mood; Body image; Sexual dysfunction; Mediating effect

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Depressive mood and body image partially mediate the relationship between menopausal symptoms and sexual function in perimenopausal women, accounting for 39.90% of the total effect. Understanding these mediating factors can help inform interventions targeting sexual dysfunction in this population.

Citation: Ling J, Wang YH. Association between depressive mood and body image and menopausal symptoms and sexual function in perimenopausal women. *World J Clin Cases* 2023; 11(32): 7761-7769

URL: <https://www.wjgnet.com/2307-8960/full/v11/i32/7761.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v11.i32.7761>

INTRODUCTION

Perimenopause is the period before and after menopause, when a woman's ovarian function begins to decline. During this period, women experience alterations in their mental state, hot flashes, sweating, excitement, and irritability[1,2], which is not conducive to physical and mental health. In addition to physical discomfort, a decrease in the hormone levels, genital tissue structure, and texture, as well as vaginal mucosal atrophy, may cause low sexual desire and difficulty in sexual arousal[3], and even worse, female sexual dysfunction (FSD), which is not good for the physical and mental health of women and is also detrimental to family harmony and quality of life[4].

Relevant studies have shown that women with severe menopausal symptoms are at higher risk of developing FSD. Besides physiological factors, the occurrence of FSD is associated with multiple non-physiological factors such as sexual health concepts, income levels, negative emotions, and body image[5,6]. Xiong *et al*[7] reported that 90% of FSD is caused by psychological factors and that body image is strongly associated with female sexual behavior[5], both of which play a non-negligible role in the mechanism of FSD. Nevertheless, there are few studies on the correlation among menopausal symptoms, depressive state, body image, and sexual function in perimenopausal women. Therefore, the present study investigated whether depressive state and body image play a mediating role between menopausal symptoms and sexual function to provide theoretical guidance for the improvement of sexual quality of life in perimenopausal women.

MATERIALS AND METHODS

Participants

A total of 186 perimenopausal women were recruited between January 2019 and January 2021. The inclusion criteria were as follows: (1) Diagnosed perimenopausal women[8]; (2) signed informed consent; (3) married, spouse alive; (4) barrier-free communication and understanding of scale content; and (5) no history of mental illness before perimenopause. The exclusion criteria were as follows: (1) Mental disease; (2) estrogen replacement therapy; (3) heart, liver, kidney, and other vital organ disorders and severe chronic diseases; and (4) abnormal sexual function of the sexual partner, without sexual life for nearly four weeks. Women with a female sexual function index (FSFI) score < 26.55 were included in the FSD group (134 cases), and the rest were included in the control group (52 cases). Participants with a Menopause Rating Scale (MRS) score < 9 were included in the mild group, those with a score of 9-16 were included in the moderate group, and those with a score > 16 were included in the severe group. This study was approved by the Affiliated Hospital of Hunan Academy of Chinese Medicine.

Methods

Research methods: Baseline data such as age, spouse age, education level, and monthly income were collected and compared between the FSD and control groups to analyze FSD-related factors in perimenopausal women. Body image

status and degree of depression [assessed using the Body Image Scale (BIS) and Hamilton Depression Scale (HAMD) scores, respectively] were compared among the mild, moderate, and severe groups. The correlation between the MRS score and BIS and HAMD scores were assessed. Additionally, the mediating effects of body image status and degree of depression on menopausal symptoms and sexual function were analyzed.

Assessment of sexual function and definition of FSD: FSFI[4] was used to measure sexual function and the scale was filled out independently by the patients. The scale contains 6 dimensions and 20 items, with 0-5 points for each dimension and 1-5 points for each item, and a total score of 36 points. The lower the score, the more severe the sexual dysfunction. FSD was defined by a total score of < 26.55.

Body image assessment: BIS[9] compiled by Hopwood *et al* was used to measure the body image of patients. The BIS scale was completed independently by patients. The scale contains 10 items with 0-3 points for each item. Zero, 1, 2, and 3 points represent “not at all,” “a little,” “quite a lot,” and “much”, respectively. The total score is 30 points, and the higher the score, the worse the body image.

Depression assessment: The HAMD[6] was used for depression assessment. The scale contains 21 items, with 0-4 scores for each item. A total score of 7-17, 17-24, and > 24 represents mild, moderate, and severe depression, respectively.

Assessment of the severity of menopausal symptoms: MRS was applied for the assessment of the severity of menopausal symptoms. The scale includes 11 items with physical, psychological, and genitourinary dimensions. Each item is scored as 0, 1, 2, 3, or 4 points for “asymptomatic,” “mild,” “moderate,” “severe,” and “very severe” symptoms, respectively. The total score is 44, with a score of < 4 for asymptomatic, 4-8 for mild, 9-16 for moderate, and 16-44 for severe symptoms.

Quality control

Before the study, two medical staff members who guided participants in filling out the questionnaire were given uniform guidance language training, and the same guidance language was applied to all participants. The questionnaire was completed independently by patients in the outpatient department and issued and collected immediately.

Statistical analysis

Data were analyzed using SPSS 25.0 (IBM Corp., Armonk, NY, United States). Measurement data were expressed as mean \pm SD. Differences between the groups were compared using the two-independent samples *t*-test. Count data were expressed as percentages [*n* (%)] and analyzed using the χ^2 test. Analysis of variance (ANOVA) was used to compare differences among three or more groups. The Bonferroni method was used for the pairwise comparisons. The corrected *P*-value (*P* < 0.017) was used for the pairwise comparisons. Ranked data were analyzed using the rank-sum test to compare differences among groups. Multivariate logistic regression was used to analyze FSD-related factors in perimenopausal women. Pearson's correlation analysis was used to analyze the correlation between the MRS score and the BIS and HAMD scores. A structural equation model of the correlation between menopausal symptoms, sexual function, body image, and depression was established to test the mediating effect of BIS and HAMD scores on the MRS score and FSFI. A mediating effect existed if the confidence interval was not 0. *P* < 0.05 was considered statistically significant.

RESULTS

Comparison of clinical data between the control and FSD groups

The HAMD and BIS scores were higher in the FSD group than in the control group (*P* < 0.05). The difference in the monthly income between the two groups was significant (*P* < 0.05). There were no significant differences in the other data between the two groups (*P* > 0.05; Table 1).

Logistic regression analysis of FSD-related factors in perimenopausal women

Monthly income of < 2000 yuan [odds ratio (OR) = 26.586, *P* = 0.000], BIS score (OR = 1.590, *P* = 0.000), and HAMD score (OR = 1.884, *P* = 0.000) were all independent risk factors for FSD (Table 2).

Comparison of MRS, BIS, HAMD, and FSFI scores in women with different degrees of menopausal symptoms

A comparison of the clinical data in women with different degrees of menopausal symptoms is shown in Table 3. The BIS and HAMD scores were lower in the mild and moderate groups than in the severe group. The FSFI scores were higher in the mild and moderate groups than in the severe group (all *P* < 0.017). The MRS scores were positively correlated with the BIS and HAMD scores (*r* = 0.358 and 0.244, *P* = 0.000 and 0.001, respectively) and negatively correlated with the FSFI scores (*r* = -0.433, *P* = 0.000; Table 4).

Analysis of the mediating effect of body image and depressive mood

Body image and depressive mood were part of the mediating effect. The mediating effect accounted for 39.90% of the total effect (-0.166/-0.416), among which the HAMD and BIS score accounted for 20.91% and 18.99%, respectively (Figure 1 and Table 5).

Table 1 Comparison of clinical data between the control and female sexual dysfunction groups [*n* (%), mean \pm SD]

Factor	Control group (<i>n</i> = 52)	FSD group (<i>n</i> = 134)	<i>t</i> / χ^2 / <i>Z</i>	<i>P</i> value
Age (yr)	47.78 \pm 4.03	48.49 \pm 3.65	-1.156	0.249
Spouse age (yr)	51.14 \pm 5.26	50.57 \pm 4.80	0.707	0.480
BMI (kg/m ²)	22.34 \pm 2.75	22.86 \pm 2.31	-1.304	0.194
Delivery times (time)	2.64 \pm 0.79	2.75 \pm 0.92	-0.760	0.448
BIS score (point)	9.33 \pm 2.87	14.63 \pm 4.52	-7.856	0.000
Education level, <i>n</i> (%)				
Junior high school and below	34 (65.38)	102 (76.12)	-1.542	0.123
Senior middle school	14 (26.92)	27 (20.15)		
College and above	4 (7.69)	5 (3.73)		
Monthly income (yuan), <i>n</i> (%)				
< 2000	21 (40.38)	100 (74.63)	-4.652	0.000
2000-5000	15 (28.85)	23 (17.16)		
> 5000	16 (30.77)	11 (8.21)		
HAMD score (point)	7.83 \pm 2.32	13.44 \pm 3.65	-10.296	0.000
Retirement, <i>n</i> (%)	24 (46.15)	66 (49.25)	0.144	0.704

BMI: Body mass index; HAMD: Hamilton Depression Scale; BIS: Body Image Scale; FSD: Female sexual dysfunction.

Table 2 Logistic regression analysis results of female sexual dysfunction-related factors in perimenopausal women

Factor	β value	Standard error	Wald	<i>P</i> value	Odds ratio	95% confidence interval
Monthly income						
> 5000 yuan			12.820	0.002	1.000	
< 2000 yuan	3.280	0.942	12.117	0.000	26.586	4.193-168.579
2000-5000 yuan	1.854	0.977	3.603	0.058	6.387	0.941-43.341
BIS score	0.464	0.107	18.941	0.000	1.590	1.290-1.959
HAMD score	0.633	0.124	25.981	0.000	1.884	1.477-2.403

HAMD: Hamilton Depression Scale; BIS: Body Image Scale.

DISCUSSION

FSD problems in perimenopausal women

Perimenopause is a process involving ovarian dysfunction and sex hormone fluctuations. This stage is accompanied by symptoms of menopause, increased risk of various chronic diseases, and decline in reproductive function[10,11], causing varying degrees of negative changes to women's physiological, psychological, and social relations. In addition to physical discomfort, another often-overlooked effect of perimenopause in women is FSD. A previous study showed that the incidence of FSD in perimenopausal women was as high as over 60%[3], which not only impacts mental health but also interferes with family harmony and stability. The occurrence of FSD cannot be separated from numerous independent risk factors. Besides physiological factors such as ovarian function decline, psychological factors also have a significant influence on the development of FSD[12]. Thus, our study investigated whether depression and body image play mediating roles.

Correlation between income and FSD

Female sexual behavior is strongly associated with several social factors. In this study, there was a significant difference in the monthly income between the FSD and control groups. A monthly income < 2000 yuan was an independent risk factor for FSD. Jin *et al*[13] reported that age, menstruation, financial status, and hormone supplementation were related to female sexual function, which is consistent with previous results[14]. This may be because perimenopausal women with higher monthly income may have better living conditions and enthusiasm to seek medical treatment for menopausal symptoms[15], leading to a relatively lower incidence of FSD.

Table 3 Comparison of clinical data in women with different degrees of menopausal symptoms [*n* (%), mean \pm SD]

Factor	Mild group (<i>n</i> = 20)	Moderate group (<i>n</i> = 83)	Severe group (<i>n</i> = 83)	<i>F/Z</i>	<i>P</i> value
Age (yr)	48.01 \pm 1.54	48.62 \pm 2.56	48.92 \pm 2.09	1.336	0.265
Spouse age (yr)	49.30 \pm 2.26	50.25 \pm 3.80	50.17 \pm 3.14	0.659	0.519
Delivery times (time)	2.24 \pm 0.57	2.50 \pm 0.96	2.58 \pm 0.78	1.301	0.275
Education level, <i>n</i> (%)					
Junior high school and below	11 (55.00)	65 (78.31)	60 (71.29)	4.484	0.106
Senior middle school	7 (35.00)	14 (16.87)	20 (24.10)		
College and above	2 (10.00)	4 (4.82)	3 (3.61)		
Monthly income (yuan), <i>n</i> (%)					
< 2000	13 (65.00)	51 (61.45)	57 (68.67)	1.468	0.480
2000-5000	5 (25.00)	16 (19.28)	17 (20.48)		
> 5000	2 (10.00)	16 (19.28)	9 (10.84)		
Retirement, <i>n</i> (%)	9 (45.00)	42 (50.60)	48 (57.83)	0.200	0.654
BMI (kg/m ²)	22.06 \pm 1.45	22.52 \pm 2.23	22.73 \pm 2.30	0.781	0.459

BMI: Body mass index.

Table 4 Comparison of Menopause Rating Scale, Body Image Scale, Hamilton Depression Scale, and female sexual function index scores in women with different degrees of menopausal symptoms (mean \pm SD, point)

Group	BIS score	HAMD score	FSFI score
Mild (<i>n</i> = 20)	10.25 \pm 3.18 ^b	10.49 \pm 3.13 ^b	26.21 \pm 3.97 ^b
Moderate (<i>n</i> = 83)	12.13 \pm 4.02 ^b	11.08 \pm 3.06 ^b	24.38 \pm 5.55 ^b
Severe (<i>n</i> = 83)	15.39 \pm 4.82 ^a	13.23 \pm 4.02 ^a	20.83 \pm 3.65 ^a
<i>F</i>	17.671	9.688	17.633
<i>P</i> value	0.000	0.000	0.000

^a*P* < 0.05 *vs* the moderate group.^b*P* < 0.05 *vs* the severe group.

HAMD: Hamilton Depression Scale; BIS: Body Image Scale; FSFI: Female sexual function index.

Table 5 Mediating effect test of body image and depressive mood

Effect		Effect	Standard error	<i>t</i>	<i>P</i> value	LLCI	ULCI
Total effect		-0.416	0.064	-6.524	0.000	-0.542	-0.290
Direct effect		-0.250	0.060	-4.159	0.000	-0.369	-0.132
Mediating effect	HAMD score	-0.087	0.028	-6.155	0.000	-0.150	-0.039
	BIS score	-0.079	0.025	-3.623	0.000	-0.138	-0.036

HAMD: Hamilton Depression Scale; BIS: Body Image Scale; LLCI: Lower limit of 95% confidence interval; ULCI: Upper limit of 95% confidence interval.

Psychological factors play an important role in the development of FSD

With increasing awareness of physical and mental diseases, the role of psychological factors in FSD has received considerable attention. The current study showed that the HAMD and BIS scores were higher in the FSD group than in the control group. Moreover, BIS and HAMD scores were independent risk factors for FSD. Body image and degree of depression are vital components of individual psychological factors. Body image is a complex experience mixed with the physical self, social self, and psychological self[16], while the degree of depression is a common negative emotion of




Figure 1 Mediating effect of Hamilton Depression Scale and Body Image Scale on Menopause Rating Scale and female sexual function index. FSFI: Female sexual function index; HAMD: Hamilton Depression Scale; BIS: Body Image Scale; MRS: Menopause Rating Scale.

perimenopausal women, and both affects women's sexual behavior at a non-physiological level. Perimenopausal women are often accompanied by depression, irritability, and fatigue due to the fluctuation of sex hormones[17]. An Iranian study[18] demonstrated that depressed emotions were associated with a loss of interest, energy, and self-esteem among patients. Women in depressed states find it difficult to express their emotions and desires, which hinders their willingness to engage in sexual behaviors[18]. Simultaneously, depressive mood was an independent risk factor for FSD in perimenopausal women[19,20]. These findings are consistent with our results. Physical and psychological changes during perimenopause can diminish self-confidence and worsen body image in women. Negative self-body image contributes to resistance to sexual behavior and thus reduces sexual desire and response[21], thereby resulting in the occurrence of FSD.

Effect of the severity of menopausal symptoms on body image and depression

Health management of menopausal women should not only address their physical condition but also their psychological needs. Our study showed that the MRS, BIS, and HAMD scores were lower in the mild and moderate groups than in the severe group. The MRS scores were positively correlated with the BIS and HAMD scores. Menopausal symptoms can affect psychological factors in perimenopausal women, and such women are often troubled by several physiological changes, such as hot flashes and sweating, insomnia, paresthesia, body shape change, and headache[10]. The discomfort induced by these menopausal symptoms can affect women's mental states and attitudes toward menopause, ultimately aggravating negative evaluations of body image and depression. Hong *et al*[22] reported that menopausal symptoms are associated with body image, depression, and sexual communication, which mediates the correlation between menopausal symptoms and sexual function. It is also indicated that the effect of menopausal symptoms on sexual function in perimenopausal women includes both physiological and psychological factors.

Correlation between menopausal symptoms, depression, body image, and sexual function

Our data showed that the MRS score was negatively correlated with the FSFI, and body image and depressive mood had a partial mediating effect on menopausal symptoms and sexual function, accounting for 39.90% of the total effect, of which the HAMD and BIS scores accounted for 20.91% and 18.99%, respectively. Specifically, the MRS score negatively predicted the HAMD and BIS scores, whereas the HAMD and BIS scores positively predicted the FSFI score. These results reveal that menopausal symptoms affect sexual function, in part, through depressive mood and body image. This suggested that the improvement in sexual function of perimenopausal women could be achieved by improving body image and mood as well as self-cognition and negative emotions. Therefore, the sexual function of perimenopausal women can be improved from a multi-dimensional perspective. In addition to sex hormone replacement therapy and pelvic floor muscle training, the following is recommended to improve the sexual function of perimenopausal women: (1) Providing sexual health education to both spouses and strengthen sexual communication; (2) psychological intervention and antidepressant medication if necessary; (3) instructing women to exercise with body image as the target; and (4) advising family members and friends to support and tolerate perimenopausal women and encourage mutual

communication. Furthermore, HAMD and BIS scores played a partial mediating role, suggesting that there may be other variables affecting sexual function, which will be the focus of future studies.

Nonetheless, this study has some limitations. The scales used are all filled out subjectively by the patients, and the samples needed to be expanded to reduce bias in the results. Moreover, there are only a handful of studies on this topic, which warrants further studies with larger sample sizes to validate our conclusions.

CONCLUSION

In summary, body image and the degree of depression in perimenopausal women have a partial mediating effect on menopausal symptoms and sexual function. In addition to the treatment of menopausal symptoms, close attention should also be paid to negative emotions and body image, to improve the sexual function in perimenopausal women.

ARTICLE HIGHLIGHTS

Research background

Perimenopause is the period when women's ovarian function begins to decline before and after menopause. During this period, women experience a series of mental state changes, such as decreased hormone levels, decreased libido, and even female sexual dysfunction (FSD) in severe cases, which reduces their quality of life. Factors affecting the occurrence of FSD include physiological and non-physiological factors, among which physiological factors are uncontrollable. Therefore, it is particularly important to ascertain the related non-physiological factors that affect the occurrence of FSD for improving the quality of sexual life of perimenopausal women.

Research motivation

To observe the related non physiological factors that affect the occurrence of perimenopausal FSD, and to improve the quality of sexual life of perimenopausal women.

Research objectives

To investigate the mediating effect of depressive mood and body image on menopausal symptoms and sexual function in perimenopausal women.

Research methods

Analysis of variance (ANOVA), Bonferroni method, rank-sum test, multivariate logistic regression, and Pearson correlation analysis.

Research results

The Hamilton Depression Scale (HAMD) and Body Image Scale (BIS) scores were higher in the FSD group than in the control group. Monthly income of < 2000 yuan, BIS score, and HAMD score were independent risk factors for FSD. The MRS scores were positively correlated with the BIS and HAMD scores and negatively correlated with the female sexual function index scores. Body image and depressive mood had partial mediating effects, accounting for 39.90% of the total effect.

Research conclusions

Depression and body image play mediating roles between menopausal symptoms and sexual function in perimenopausal women.

Research perspectives

This study shows that depression and body image play mediating roles between menopausal symptoms and sexual function in perimenopausal women, and reasonable countermeasures can be considered in clinic.

FOOTNOTES

Author contributions: Ling J and Wang YH contributed equally to this work; Ling J and Wang YH designed the study; Ling J contributed to the analysis of the manuscript; Ling J and Wang YH were involved in the data and writing of this article; and all authors have read and approved the final manuscript.

Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of Hunan University of Chinese Medicine.

Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

Conflict-of-interest statement: The authors declare no conflicts of interest regarding the content, authorship, and/or publication of this article.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Jia Ling 0000-0003-2242-0332; Yu-Hong Wang 0000-0003-2285-6339.

S-Editor: Yan JP

L-Editor: A

P-Editor: Yan JP

REFERENCES

- Willi J, Ehler U. Assessment of perimenopausal depression: A review. *J Affect Disord* 2019; **249**: 216-222 [PMID: 30776662 DOI: 10.1016/j.jad.2019.02.029]
- Khanna A, John F, Das S, Thomas J, Rao J, Maliakel B, Im K. Efficacy of a novel extract of fenugreek seeds in alleviating vasomotor symptoms and depression in perimenopausal women: A randomized, double-blinded, placebo-controlled study. *J Food Biochem* 2020; **44**: e13507 [PMID: 33025616 DOI: 10.1111/jfbc.13507]
- Gordon JL, Halleran M, Beshai S, Eisenlohr-Moul TA, Frederick J, Campbell TS. Endocrine and psychosocial moderators of mindfulness-based stress reduction for the prevention of perimenopausal depressive symptoms: A randomized controlled trial. *Psychoneuroendocrinology* 2021; **130**: 105277 [PMID: 34058560 DOI: 10.1016/j.psyneuen.2021.105277]
- Martins WP, Lara LA, Ferriani RA, Rosa-E-Silva AC, Figueiredo JB, Nastri CO. Hormone therapy for female sexual function during perimenopause and postmenopause: a Cochrane review. *Climacteric* 2014; **17**: 133-135 [PMID: 23895350 DOI: 10.3109/13697137.2013.828688]
- Mishra VV, Nanda S, Vyas B, Aggarwal R, Choudhary S, Saini SR. Prevalence of female sexual dysfunction among Indian fertile females. *J Midlife Health* 2016; **7**: 154-158 [PMID: 28096637 DOI: 10.4103/0976-7800.195692]
- Kucur Suna K, Ilay G, Aysenur A, Kerem Han G, Eda Ulku U, Pasa U, Fatma C. Effects of Infertility Etiology and Depression on Female Sexual Function. *J Sex Marital Ther* 2016; **42**: 27-35 [PMID: 25629442 DOI: 10.1080/0092623X.2015.1010673]
- Xiong XT, Jin LJ. Research advance on the relationship between hypertension, antihypertensive drugs and female sexual function. *Zhonghua Gaoxueya Zazhi* 2019; **27**: 323-326
- Ruan XY, Yang X. Expert consensus on the diagnosis and treatment of perimenopausal abnormal uterine bleeding. *Xiehe Yixue Zazhi* 2018; **9**: 313-319
- Paterson CL, Lengacher CA, Donovan KA, Kip KE, Toft-Hagen CS. Body Image in Younger Breast Cancer Survivors: A Systematic Review. *Cancer Nurs* 2016; **39**: E39-E58 [PMID: 25881807 DOI: 10.1097/NCC.0000000000000251]
- Culbert KM, Thakkar KN, Klump KL. Risk for midlife psychosis in women: critical gaps and opportunities in exploring perimenopause and ovarian hormones as mechanisms of risk. *Psychol Med* 2022; **52**: 1612-1620 [PMID: 35582864 DOI: 10.1017/S0033291722001143]
- Kanadys K, Wiktor-Stoma A, Lewicka M, Sulima M, Wiktor H. Predictors of the quality of life of women in peri-menopausal period. *Ann Agric Environ Med* 2016; **23**: 641-648 [PMID: 28030937 DOI: 10.5604/12321966.1226860]
- Dombek K, Capistrano EJ, Costa AC, Marinheiro LP. Risk factors associated with sexual dysfunction in Brazilian postmenopausal women. *Int J Impot Res* 2016; **28**: 62-67 [PMID: 26865103 DOI: 10.1038/ijir.2016.4]
- Jin FY, Ruan XY, Mueck AO, Liu YL, Du J. Investigation on sexual dysfunction of female patients in hospital (analysis of 420 cases). *Beijing Yixue* 2017; **39**: 1135-1137
- Yisma E, Eshetu N, Ly S, Dessalegn B. Prevalence and severity of menopause symptoms among perimenopausal and postmenopausal women aged 30-49 years in Gulele sub-city of Addis Ababa, Ethiopia. *BMC Womens Health* 2017; **17**: 124 [PMID: 29216870 DOI: 10.1186/s12905-017-0484-x]
- Li RX, Ma M, Xiao XR, Xu Y, Chen XY, Li B. Perimenopausal syndrome and mood disorders in perimenopause: prevalence, severity, relationships, and risk factors. *Medicine (Baltimore)* 2016; **95**: e4466 [PMID: 27512863 DOI: 10.1097/MD.0000000000004466]
- Chang SR, Yang CF, Chen KH. Relationships between body image, sexual dysfunction, and health-related quality of life among middle-aged women: A cross-sectional study. *Maturitas* 2019; **126**: 45-50 [PMID: 31239117 DOI: 10.1016/j.maturitas.2019.04.218]
- Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, Bobo WV, Rubin LH, Koleva HK, Cohen LS, Soares CN. Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations. *J Womens Health (Larchmt)* 2019; **28**: 117-134 [PMID: 30182804 DOI: 10.1089/jwh.2018.27099.mensocrec]
- Yazdanpanahi Z, Nikkholgh M, Akbarzadeh M, Pourahmad S. Stress, anxiety, depression, and sexual dysfunction among postmenopausal women in Shiraz, Iran, 2015. *J Family Community Med* 2018; **25**: 82-87 [PMID: 29922107 DOI: 10.4103/jfcm.JFCM_117_17]
- Kucukdurmaz F, Inanc Y, Resim S. Sexual dysfunction and distress in premenopausal women with migraine: association with depression, anxiety and migraine-related disability. *Int J Impot Res* 2018; **30**: 265-271 [PMID: 30068979 DOI: 10.1038/s41443-018-0049-z]
- Gozuyesil E, Gokyildiz Surucu S, Alan S. Sexual function and quality-of-life-related problems during the menopausal period. *J Health Psychol* 2018; **23**: 1769-1780 [PMID: 29243521 DOI: 10.1177/1359105317742194]

- 21 **Nazarpour S**, Simbar M, Tehrani FR. Factors affecting sexual function in menopause: A review article. *Taiwan J Obstet Gynecol* 2016; **55**: 480-487 [PMID: [27590367](#) DOI: [10.1016/j.tjog.2016.06.001](#)]
- 22 **Hong JH**, Kim HY, Kim JY, Kim HK. Do psychosocial variables mediate the relationship between menopause symptoms and sexual function in middle-aged perimenopausal women? *J Obstet Gynaecol Res* 2019; **45**: 1058-1065 [PMID: [30767331](#) DOI: [10.1111/jog.13927](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

